调节肠道微生态治疗肠易激综合征

发布时间：2018-06-01 17:15

本文选题：肠道微生态 + 肠易激综合征　；参考：《中国实用儿科杂志》2017年02期

【摘要】：肠易激综合征(IBS)是儿童慢性腹痛的常见原因,发病率高,长期可严重影响生活质量。IBS确切发病机制不明,近年发现,肠道微生态失平衡与IBS关系密切,IBS患者肠道微生物定植抗力受损(B/E值降低),肠道微生物总体的多样性和稳定性普遍降低,大肠杆菌和肠球菌属数量增加,双歧杆菌和乳酸杆菌数量减少。IBS无特异性的治疗方法,调节肠道微生态是治疗IBS的重要靶点。益生菌可作为IBS治疗的辅助手段,能否作为主要治疗药物加以推荐尚需更充分的临床证据,确切疗效尚需要开展高质量的临床双盲、随机、对照研究进一步验证,尚无证据表明益生元、合生元、粪菌移植(FMT)可用于治疗IBS。利福昔明治疗IBS可能有效,但需要更多的证据。
[Abstract]:Irritable bowel syndrome (IBS) is a common cause of chronic abdominal pain in children. There was a close relationship between intestinal microecological imbalance and IBS. The B / E value of intestinal microbial colonization resistance was decreased, the total diversity and stability of intestinal microorganism was decreased, and the number of Escherichia coli and Enterococcus increased. The number of Bifidobacterium and Lactobacillus is reduced. There is no specific treatment for IBS. Regulation of intestinal microecology is an important target for the treatment of IBS. Probiotics can be used as an auxiliary method for IBS treatment. Whether they can be recommended as the main therapeutic drugs still needs more sufficient clinical evidence. The exact effect of probiotics still needs to carry out high quality clinical double blind, randomized, and further verified by controlled study. There is no evidence that probiotics, congeners and faecal bacteria can be used in the treatment of IBS. Rifaximin may be effective in the treatment of IBS, but more evidence is needed.
【作者单位】：浙江大学医学院附属儿童医院;
【分类号】：R725.7

【参考文献】